Faes Farma, S.A.

As of December 31, 2024, Faes Farma, S.A. carries a market capitalization of 1.08B, placing it among publicly traded companies globally. Its enterprise value stands at 1.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Faes Farma, S.A.'s next confirmed earnings release is scheduled for February 26, 2027.

As of December 31, 2024, Faes Farma, S.A. has 311.25M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Faes Farma, S.A. maintains a current ratio of 3.23, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended December 31, 2024, Faes Farma, S.A. recorded an income tax benefit of -3.54M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, Faes Farma, S.A.'s stock has gained approximately 4.32% over the past 52 weeks. The 50-day moving average sits at 4.63, while the 200-day moving average is 4.72.

As of December 31, 2024, Faes Farma, S.A. holds 72.14M in cash and equivalents against 22.90M in total debt, resulting in a net debt position of -47.13M. Total book value stands at 725.87M, with working capital of 230.27M providing operational flexibility.

Faes Farma, S.A.'s most recent stock split took place on April 7, 2015 with a 50:51 split ratio.